Guidance in the Red / Amber List serves ONLY to define where clinical and prescribing responsibility for the listed medicines should lie in terms of governance and safety.
- Inclusion in this list does NOT imply the medicine has been accepted for use via Managed Entry, does NOT imply endorsement of use, and does NOT take account of the cost implications of use of a particular medicine.
- Prescribers should use this list in conjunction with guidance on the Managed entry process for medicines, and the NI formulary which includes information on current cost effective choices.
- For information relating to the Local Enhanced Service (NILES) relating to Additional Monitoring of Amber Drugs click here
- As far as possible, new specialist medicines are added to the list at the point when they are granted a UK product licence. In some instances this may be prior to the medicine being launched.
The table below lists specialist medicines. Users should search by generic name where possible. Brand names listed are not exhaustive.
Click to Show NEW entries only or limit alphabetically (by generic name): A-B C-D E-J K-M N-R S-Z
| Approved Name | Example Trade Names | Context | Status | Guidance | New Entry |
|---|---|---|---|---|---|
| Warfarin | Amber sub-group | Local Arrangements For Shared Care May Apply | |||
| Zanubrutinib | Brukinsa | Red | |||
| Zidovudine | Retrovir | Red | |||
| Zidovudine with lamivudine | Combivir | Red | |||
| Zilucoplan | Zilbrysq | Red | NEW | ||
| Zolbetuximab | Vyloy | Red | |||
| Zoledronic acid | Aclasta, Zometa | Red |
- 1
- 2
You can also Download the Red Amber List as a CSV file